ACT-1 is our preclinical activator program targeting DCM due to sarcomeric mutations and impaired calcium regulation.  In preclinical models, our ACT-1 prototype molecules successfully increase contractility, without prolonging systolic ejection time and with minimal impact on relaxation. We currently anticipate advancing our first ACT-1 program compound into clinical development in late 2020 or early 2021.